Researchers discover sustainable and natural alternative to man-made chemical pesticides

Phys.org | March 04, 2019

Repurposing a strain of beneficial bacteria could offer a safe, sustainable and natural alternative to man-made chemical pesticides, according to research from Cardiff University. Finding natural approaches to sustainable agriculture and food production is a major global challenge. Synthetic chemical pesticides have traditionally been used to protect crops, but there are growing concerns around their toxicity and the threat they pose to ecosystems. Using genomic techniques, the team of researchers discovered that Burkholderia ambifaria bacteria have the potential to be used as biopesticides that are both effective and safe. Biopesticides offer a natural means of protection and the group of bacteria called Burkholderia have been successfully used to protect crops against diseases. However, in the 1990s, Burkholderia bacteria were linked to serious lung infections in people with cystic fibrosis (CF), leading to concerns about their safety and eventual withdrawal of these biopesticides from the market.

Spotlight

When you made coffee this morning, you probably didn't realize the filter was made with a biotechnology process that uses enzymes to bleach the paper, reducing the amount of chlorine and energy used in manufacturing. The vitamin C and vitamin B2 you gulped this morning were probably made with a biotech process that eliminates the use of toxic chemicals during the manufacturing proces

Spotlight

When you made coffee this morning, you probably didn't realize the filter was made with a biotechnology process that uses enzymes to bleach the paper, reducing the amount of chlorine and energy used in manufacturing. The vitamin C and vitamin B2 you gulped this morning were probably made with a biotech process that eliminates the use of toxic chemicals during the manufacturing proces

Related News

MEDICAL

Recipharm and Moderna Finalize Agreement to Support Formulation and Fill-Finish a part of the Moderna COVID-19 Vaccine Supply Outside of the U.S.

Recipharm | January 04, 2021

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the immunization in important nations outside of the U.S., it is anticipated that supply will commence in early 2021. “We are making important progress in the development of the Moderna COVID-19 Vaccine and we are pleased to be entering into this collaboration with Recipharm,” said Nicolas Chornet, Senior Vice President, International Manufacturing of Moderna. “We look forward to their support in the delivery of our vaccine to market.”

Read More

MEDICAL

MindMed Announces the start of the First Ever Clinical Trial Measuring and Evaluating MDMA and LSD

MindMed | January 21, 2021

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and nervousness that are sometimes associated with LSD - creating a general more good experience. MindMed is undertaking a Phase 1 clinical preliminary to assess if MDMA, when adjusted and utilized in combination with LSD, can help offset a portion of the known expected horrendous impacts of LSD that happen in treatment or clinical settings. MindMed is keen on arrangement how to adjust both MDMA and LSD in a strong manner to make better patient results, and grow further developed hallucinogenic helped treatments, as MindMed extends the two its R&D and commercial drug improvement pipeline. The examination is foreseen to take around one year to finish.

Read More

Ori Biotech Raises $30 Million $30 Million Series A Financing Round to Advance Innovation in Cell and Gene Therapy Manufacturing

Ori Biotech | October 15, 2020

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor syndicate was led by the experienced life sciences investment team at Northpond Ventures, a leading global science, medical, and technology-driven venture fund, alongside Octopus Ventures, a leading European venture fund. Northpond and Octopus invested alongside significant support from Ori's existing institutional investors, Amadeus Capital Partners, Delin Ventures, and Kindred Capital. "Closing a significant Series A round, during these uncertain times, further validates Ori's disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality, and decrease costs," said Jason C. Foster, CEO of Ori Biotech. "We are excited to work with our top tier investors and development partners to bring our platform to market as fast as possible to achieve our mission of enabling patient access to life-saving cell and gene therapies." "As early investors in disruptive life sciences platform technology companies, we have seen how cutting-edge technologies like Ori's can bring significant value to the industry and lead to breakthroughs for patients," said Michael Rubin, M.D., Ph.D., Founder and CEO of Northpond Ventures. "We believe that the Ori team has developed a truly innovative technology that can enable millions of patients to gain access to these important treatments." Ori's bespoke platform was designed specifically to address the unique requirements of a new generation of personalized cell and gene therapies. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial-scale manufacturing. Its flexible platform enables increased throughput, improved quality, and decreased costs.

Read More